New Biotech Firm to Launch NASH, and More

Vita Therapeutics: The Baltimore, Maryland-based Firm announced a $32 million Series A funding round oversubscribed. Cambrian Biopharma led the way, with Kiwoom Bio, SCM Life Sciences, and Early Light Ventures joining in. VTA-100, Vita’s primary therapy, is developed for LGMD 2A/R1 (limb-girdle muscular dystrophy). To help repair and replace muscle cells, it combines gene correction with induced pluripotent stem cell (iPSC) technologies.

VTA-200, the company’s second product, is a hypoimmunogenic treatment for numerous kinds of muscular dystrophy produced from genetically modified iPSCs. NuvoAir: NuvoAir is a Boston-based startup that just raised $12 million in Series A financing. AlbionVC was in charge. KAYA, Amino Collective, and current owners Spiltan, Industrifonden, and Novartis Pharma AG also took part.

NuvoAir is a digital health company that specializes in respiratory issues. The $12 million will give patients and doctors chronic illness management and clinical trial platforms. It consists of a patient app with connected devices, self-management content, care coordination services, and a member portal. A Bluetooth-enabled spirometer, a sensor for asthma and COPD inhalers, and Fitbit integration are also included.

Enveda Biosciences: The Boulder, Colorado-based Firm announced a $51 million Series A investment oversubscribed. Lux Capital led the round, which included current investors True Ventures, Wireframe Ventures, Village Global, Chris Gibson of Recursion, and Two Sigma Ventures, Hummingbird VC, Catalio Capital, Lifeforce Capital, and Matthew De Silva of Notable Labs.Enveda, which was founded in 2019, uses machine learning and metabolomics to identify medicinal value in plants. According to the business, multiple lead compounds, including possibilities for Wilson’s disease, NASH, and Parkinson’s disease, are on track.